ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1275

Fast Remission Response to Etanercept At Week 4 Predicts Better Long-Term Outcomes in Early and Established Rheumatoid Arthritis Compared to Slower Response At Week 12

Bernd Raffeiner1, Costantino Botsios2, Francesca Ometto2, Mariagrazia Canova2, Livio Bernardi2, Cristiana Vezzari2, Silvano Todesco2, Paolo Sfriso2 and Leonardo Punzi2, 1Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, 2Clinical and Experimental Medicine, Rheumatology Unit - University of Padova, Padova, Italy

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: etanercept, prognostic factors, remission and rheumatoid arthritis, treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy

Session Type: Abstract Submissions (ACR)

Background/Purpose: Achievement of clinical remission not only early in disease course but also early in treatment course may be critical for functional outcome of patients with rheumatoid arthritis (RA). Patients showing clinical response to certolizumab at week 6 demonstrated greater ACR responses, higher rates of remission, and improved patient-reported outcomes after 1 year compared to patients who had a response at week 12. Response to treatment as early as week 6 predicted continuation of treatment with TNFα blockers in long-term follow-up. Objective of study was to establish rate of patients on etanercept (ETA) achieving clinical remission at week 4 (fast) or week 12 of treatment (slow remission responders). To determine effects of fast versus slow remission response on clinical and radiographic remission. To identify predictors for fast remission response.

Methods: Retrospective case control study was performed on RA patients who started ETA from 2004 to 2010 due to moderate-severe disease activity despite DMARDs. Patients having available control at first and third month were enrolled. Patients achieving DAS28 remission by first month were defined as fast remission responders. Patients reaching DAS28 remission at three month as slow remission responders. Patients not reaching remission within 3 months or not maintaining remission for at least one year were excluded because considered unresponsive. Fast remission responders were compared with slow responders regarding maintenance of clinical remission on ETA in longterm follow-up. Arrest of radiolgraphic progression was determined by Total Sharp Score modified van der Heijde (TSS) on X-rays performed at baseline and after 1 year. Clinical and therapeutic baseline characteristics were compared between fast and slow remission responders. Statistical analysis was performed by Student T-test and Pearson test as appropriate. Multivariate logistic regression was applied to find predictors for fast remission response.

Results: 74 of total 186 RA patients identified reached DAS28 remission within the first treatment month with ETA and were classified as fast remission responders (39.7%). Only 8 of 74 fast remission responders (10.8%) lost disease control by ETA in follow-up (mean 3.5 years) compared with 25% of slow remission responders (28 out of 112, p < 0.05). Considering patients with early RA (disease duration ≤ 1 year) difference was even more significant (14.3 vs 64.7%, p <0.05). Radiographic progression (ΔTSS>1) occurred in 5.8% of fast but 16.3% of slow remission responders (p < 0.05). No difference was found for analyzed patients’ baseline characteristics or past and concomitant therapy. None of the baseline characteristics was predictive for fast remission response.

Conclusion: Fast remission response to ETA at week 4 was achieved in 39.7% of RA patients with early and established disease, and determined better outcome by greater maintenance of clinical and radiographic remission compared to slow remission responders at week 12. Fast remission response resulted to be an independent factor for outcome as it could not be predicted by other parameters but only clinically assessed by tight control.


Disclosure:

B. Raffeiner,
None;

C. Botsios,
None;

F. Ometto,
None;

M. Canova,
None;

L. Bernardi,
None;

C. Vezzari,
None;

S. Todesco,
None;

P. Sfriso,
None;

L. Punzi,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fast-remission-response-to-etanercept-at-week-4-predicts-better-long-term-outcomes-in-early-and-established-rheumatoid-arthritis-compared-to-slower-response-at-week-12/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology